Overview: TPMT3A TestIntroduction: The TPMT3A Test tests for TPMT3A mutation to assess risk for drug toxicity in chemotherapy, helping guide safe treatment dosing. Affecting 1 in 300 patients on thiopurines, TPMT variants pose diagnostic challenges due to variable metabolism. Following 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: TPMT3A Mutation Test, Thiopurine Toxicity Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: TPMT3A testing began in the 1990s with research by Weinshilboum, who identified the variant. PCR/sequencing advancements by Illumina improved detection, surpassing earlier genotyping methods.
Purpose: Detects TPMT3A mutation status to assess chemotherapy toxicity risk, guides dosing adjustments, and evaluates patients with chemotherapy history, aiming to prevent toxicity.
Test Parameters: TPMT3A mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of chemotherapy.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document chemotherapy history. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., toxicity), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutation, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation suggests toxicity risk, guiding dosing. Early adjustment might prevent adverse effects, while untreated cases lead to complications. Normal results may require standard dosing.
Specialist Consultation: Consult an oncologist or pharmacologist for interpretation.
Additional Supporting Tests: TPMT enzyme activity, blood counts, or genetic panel to confirm diagnosis.
Test Limitations: Specific to TPMT3A; correlation with clinical status needed. False negatives possible with other variants.
References: CPIC Guidelines, 2023; Clinical Pharmacology & Therapeutics, Weinshilboum RM, 2022.
